|
(Health-NewsWire.Net, July 22, 2015 ) Soft Tissue Sarcoma - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Soft Tissue Sarcoma - Pipeline Review, H1 2015” which provides an overview of the Soft Tissue Sarcoma therapeutic pipeline.
This report gives far reaching data on the restorative advancement for Soft Tissue Sarcoma, complete with similar examination at different stages, therapeutics evaluation by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent redesigns, and included news and press discharges. It additionally audits key players included in the restorative improvement for Soft Tissue Sarcoma and uncommon elements on late-stage and ceased activities.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H1, 2015 Pipeline Review of “Soft Tissue Sarcoma” addition with 75 market data tables and 16 figures, spread across 386 pages is http://www.rnrmarketresearch.com/soft-tissue-sarcoma-pipeline-review-h1-2015-market-report.html .
This report highlights investigational medications from crosswise over globe covering more than 20 treatment regions and almost 3,000 signs. The report is manufactured utilizing information and data sourced from our databases, Company/University sites, SEC filings, speculator presentations and included press discharges from organization/college locales and industry-particular outsider sources, set up together by Global Markets Direct's group. Medication profiles/records highlighted in the report experiences intermittent updation taking after a stringent arrangement of procedures that guarantees that every one of the profiles are redesigned with the most recent arrangement of data. Also, procedures including live news & arrangements following, program based ready box and clinical trials registries following guarantee that the latest advancements are caught on an ongoing premise.
Companies Discussed/Mentioned in this Research:
Advenchen Laboratories, LLC, Altor BioScience Corporation, Amgen Inc., Bayer AG, Bellicum Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CASI Pharmaceuticals Inc., Celgene Corporation, Cellectar Biosciences, Inc., CytRx Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, EpiZyme, Inc., Exelixis, Inc., Gem Pharmaceuticals, LLC, Immune Design Corp., Karyopharm Therapeutics, Inc., Loxo Oncology, Inc., MedImmune, LLC, Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Mirati Therapeutics Inc., MolMed S.p.A., Morphotek, Inc., Nanobiotix, Neotropix, Inc., Novartis AG, Oncos Therapeutics Ltd., Onxeo SA, Pfizer Inc., Pharma Mar, S.A., Plexxikon Inc., Polaris Pharmaceuticals, Inc., Recombio S.L, Rigontec GmbH, Sanofi, Shionogi & Co., Ltd., Siena Biotech S.p.A., Sigma-Tau S.p.A., Sumitomo Dainippon Pharma Co., Ltd., Threshold Pharmaceuticals, Inc., TRACON Pharmaceuticals, Inc. and Vicore Pharma AB
Drugs Profile Discussed in this Research :
afatinib, AL-3818, aldoxorubicin hydrochloride, ALT-836, APC-103, belinostat, BI-853520, C-21, cabazitaxel, cabozantinib s-malate, cancer vaccine, Cell Therapy 2 for Oncology and Infectious Disease, Cell Therapy for GD2 Expressing Solid Tumors, Cell Therapy to Target LMP-1 and LMP-2 for Oncology, Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases, celyvir, Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology, Dendritic Cells + Cytokine Induced Killer Cells, DSR-6434, durvalumab + tremelimumab, E-6438, efatutazone, ENMD-2076, eribulin mesylate, everolimus, evofosfamide, G-100, ganitumab, GPX-150, I131-CLR1404, ImOl-100, irinotecan sucrosofate liposomal, KRA-0008, LK-3, LOXO-101, mocetinostat, MVXONCO-1, NBTX-TOPO, NBTXR-3, NGR-hTNF, NOV-110501, NTX-010, olaratumab, ONCOS-102, ontuxizumab, paclitaxel albumin bound, palbociclib, panobinostat, pazopanib hydrochloride, pembrolizumab, Peptide to Target COX-2 and MAS-GPCR for Oncology, PLX-7486, regorafenib, ribociclib, S-588410, sabarubicin, selinexor, SEN-461, SST-0001, talimogene laherparepvec, TNF-PEG 20, trabectedin, TRC-105 and vorinostat
Inquire for discount on this report http://www.rnrmarketresearch.com/contacts/discount?rname=395201 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Cancer Therapeutics Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
